Small molecule (Molecular glue degrader) · Degrader of IRAK4, Ikaros (IKZF1) and Aiolos (IKZF3) · developed by Kymera Therapeutics
Zomiradomide (KT-413) is a small molecule protein degrader that recruits the E3 ubiquitin ligase to tag IRAK4, Ikaros (IKZF1) and Aiolos (IKZF3) for proteasomal degradation. It is being studied in non-Hodgkin lymphoma, including diffuse large B-cell lymphoma with MYD88 mutations.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05233033 | Phase 1 | Non Hodgkin Lymphoma | Completed | KYMR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Large B Cell LymphomaDLBCLMYD88 Gene MutationNon Hodgkin Lymphoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the KYMR page.
See KYMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYMR catalysts and pipeline →